Grand Pharmaceutical Group Limited (0512.HK)
HKD 4.76
(-0.83%)
HKD 4.76
(-0.83%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 6.52 Billion HKD | 9.62% |
| 2022 | 5.95 Billion HKD | 13.42% |
| 2021 | 5.24 Billion HKD | 30.04% |
| 2020 | 4.03 Billion HKD | 0.05% |
| 2019 | 4.03 Billion HKD | 27.57% |
| 2018 | 3.16 Billion HKD | 27.51% |
| 2017 | 2.47 Billion HKD | 43.12% |
| 2016 | 1.73 Billion HKD | 28.28% |
| 2015 | 1.35 Billion HKD | 13.14% |
| 2014 | 1.19 Billion HKD | 34.64% |
| 2013 | 886.53 Million HKD | 37.41% |
| 2012 | 645.18 Million HKD | 25.25% |
| 2011 | 515.09 Million HKD | 37.43% |
| 2010 | 374.8 Million HKD | 49.87% |
| 2009 | 250.09 Million HKD | 127.88% |
| 2008 | 109.74 Million HKD | 384.44% |
| 2007 | 22.65 Million HKD | 19.42% |
| 2006 | 18.97 Million HKD | -5.57% |
| 2005 | 20.08 Million HKD | -2.32% |
| 2004 | 20.56 Million HKD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 3.59 Billion HKD | 0.0% |
| 2023 FY | 6.52 Billion HKD | 9.62% |
| 2023 Q2 | 3.86 Billion HKD | 0.0% |
| 2023 Q4 | 2.65 Billion HKD | 0.0% |
| 2022 FY | 5.95 Billion HKD | 13.42% |
| 2022 Q2 | 3.26 Billion HKD | 0.0% |
| 2022 Q4 | 2.69 Billion HKD | 0.0% |
| 2021 Q4 | 2.35 Billion HKD | 0.0% |
| 2021 FY | 5.24 Billion HKD | 30.04% |
| 2021 Q2 | 2.89 Billion HKD | 0.0% |
| 2020 Q4 | 1.99 Billion HKD | 0.0% |
| 2020 Q2 | 2.03 Billion HKD | 0.0% |
| 2020 FY | 4.03 Billion HKD | 0.05% |
| 2019 Q4 | 1.76 Billion HKD | 0.0% |
| 2019 FY | 4.03 Billion HKD | 27.57% |
| 2019 Q2 | 2.26 Billion HKD | 0.0% |
| 2018 FY | 3.16 Billion HKD | 27.51% |
| 2018 Q2 | 1.86 Billion HKD | 0.0% |
| 2018 Q4 | 1.29 Billion HKD | 0.0% |
| 2017 FY | 2.47 Billion HKD | 43.12% |
| 2017 Q2 | 1.15 Billion HKD | 0.0% |
| 2017 Q4 | 1.32 Billion HKD | 0.0% |
| 2016 Q4 | 970.85 Million HKD | 0.0% |
| 2016 Q2 | 761.57 Million HKD | 0.0% |
| 2016 FY | 1.73 Billion HKD | 28.28% |
| 2015 Q4 | 733.97 Million HKD | 0.0% |
| 2015 Q2 | 616.5 Million HKD | 0.0% |
| 2015 FY | 1.35 Billion HKD | 13.14% |
| 2014 Q4 | 613.03 Million HKD | 0.0% |
| 2014 Q2 | 580.61 Million HKD | 0.0% |
| 2014 FY | 1.19 Billion HKD | 34.64% |
| 2013 Q4 | 462.64 Million HKD | 0.0% |
| 2013 FY | 886.53 Million HKD | 37.41% |
| 2013 Q2 | 423.88 Million HKD | 0.0% |
| 2012 Q2 | 161.29 Million HKD | 0.0% |
| 2012 FY | 645.18 Million HKD | 25.25% |
| 2012 Q4 | 221.63 Million HKD | 37.41% |
| 2012 Q3 | 161.29 Million HKD | 0.0% |
| 2012 Q1 | 161.29 Million HKD | 0.0% |
| 2011 Q2 | 128.77 Million HKD | 0.0% |
| 2011 Q3 | 128.77 Million HKD | 0.0% |
| 2011 Q4 | 161.29 Million HKD | 25.25% |
| 2011 FY | 515.09 Million HKD | 37.43% |
| 2011 Q1 | 128.77 Million HKD | 0.0% |
| 2010 Q1 | 93.7 Million HKD | 0.0% |
| 2010 Q3 | 93.7 Million HKD | 0.0% |
| 2010 Q4 | 128.77 Million HKD | 37.43% |
| 2010 FY | 374.8 Million HKD | 49.87% |
| 2010 Q2 | 93.7 Million HKD | 0.0% |
| 2009 Q1 | 62.52 Million HKD | 0.0% |
| 2009 Q3 | 62.52 Million HKD | 0.0% |
| 2009 Q4 | 93.7 Million HKD | 49.87% |
| 2009 FY | 250.09 Million HKD | 127.88% |
| 2009 Q2 | 62.52 Million HKD | 0.0% |
| 2008 Q2 | 27.43 Million HKD | 0.0% |
| 2008 Q4 | 62.52 Million HKD | 127.88% |
| 2008 Q1 | 27.43 Million HKD | 0.0% |
| 2008 FY | 109.74 Million HKD | 384.44% |
| 2008 Q3 | 27.43 Million HKD | 0.0% |
| 2007 Q1 | 5.66 Million HKD | 0.0% |
| 2007 Q4 | 27.43 Million HKD | 384.44% |
| 2007 Q3 | 5.66 Million HKD | 0.0% |
| 2007 Q2 | 5.66 Million HKD | 0.0% |
| 2007 FY | 22.65 Million HKD | 19.42% |
| 2006 Q4 | 5.66 Million HKD | 19.42% |
| 2006 FY | 18.97 Million HKD | -5.57% |
| 2006 Q2 | 4.74 Million HKD | 0.0% |
| 2006 Q3 | 4.74 Million HKD | 0.0% |
| 2006 Q1 | 4.74 Million HKD | 0.0% |
| 2005 Q2 | 5.02 Million HKD | 0.0% |
| 2005 Q4 | 4.74 Million HKD | -5.57% |
| 2005 FY | 20.08 Million HKD | -2.32% |
| 2005 Q1 | 5.02 Million HKD | 0.0% |
| 2005 Q3 | 5.02 Million HKD | 0.0% |
| 2004 Q2 | 5.14 Million HKD | 0.0% |
| 2004 Q3 | 5.14 Million HKD | 0.0% |
| 2004 Q1 | 5.14 Million HKD | 0.0% |
| 2004 Q4 | 5.02 Million HKD | -2.32% |
| 2004 FY | 20.56 Million HKD | 0.0% |
| 2003 Q4 | 5.14 Million HKD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | -3796.454% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -22569.537% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | -1552.445% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 18424.484% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | -1083.373% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | -323.835% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | -1284.294% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -2911.631% |
| SSY Group Limited | 3.48 Billion HKD | -86.98% |
| JBM (Healthcare) Limited | 319.41 Million HKD | -1942.498% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | -951.463% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 84.956% |